How to Select the Right Subjects for Bioavailability and Bioequivalence Trials

Introduction: Why Subject Selection Is Critical for BA/BE Trials

In bioavailability and bioequivalence (BA/BE) studies, the accuracy of pharmacokinetic (PK) parameters heavily depends on the subject population. Unlike large-scale efficacy trials, BA/BE studies focus on assessing the rate and extent of drug absorption, typically under controlled conditions. Selecting an appropriate study population is therefore crucial—not only for scientific accuracy but also to comply with regulatory expectations.

Global regulatory agencies such as the NIHR, US FDA, EMA, CDSCO (India), and Health Canada provide detailed guidance on study subject criteria. They expect a consistent rationale for inclusion and exclusion, safety measures, and demographic balance. An error in population selection can lead to invalid or rejected study data, increased variability, or ethical non-compliance.

Healthy Volunteers vs Patients: Regulatory Preferences

Most BA/BE studies are conducted in healthy adult volunteers. This is because healthy subjects help reduce intersubject variability, providing a cleaner pharmacokinetic profile. Regulatory agencies almost always recommend healthy subjects unless a study drug is associated with severe side effects or is indicated only in patients.

When to use healthy volunteers:

• Systemic absorption is measurable and safe
• Drug has no significant risk or toxicity
• Therapeutic indication does not affect PK

When to use patients:

• The drug has known toxicity in healthy subjects (e.g., chemotherapy)
• Drug effect or metabolism is dependent on disease state
• Drug is locally acting and systemic absorption is minimal

Standard Inclusion Criteria: Age, BMI, and Lifestyle

According to FDA and EMA guidance, the typical age range for BA/BE participants is 18 to 55 years, with a Body Mass Index (BMI) of 18.5 to 30 kg/m². Volunteers should be non-smoking or light smokers and not under medication that affects metabolic enzymes (e.g., CYP450).

Common inclusion criteria:

• Healthy males and/or females aged 18–55 years
• Normal medical history, physical exam, and vital signs
• Negative pregnancy test for women of childbearing potential
• Ability to comply with fasting and protocol restrictions

Some studies may allow broader ranges, such as up to 65 years, especially if the drug is intended for elderly populations. However, this requires additional safety oversight and justification in the protocol.

Exclusion Criteria: Safety First

Protecting participants is a cornerstone of BA/BE studies. Regulatory bodies emphasize excluding individuals who may experience harm or confound PK results. Typical exclusion criteria include:

• History of hypersensitivity to the drug or class
• Smoking more than 10 cigarettes/day
• Alcohol or drug abuse
• Recent participation in another clinical trial (usually within 3 months)
• Blood donation within past 3 months
• Abnormal lab values or ECG

For female participants, additional exclusions include lactation and inadequate contraception. For instance, women must agree to use hormonal contraception, IUDs, or barrier methods during the study and for a defined period afterward.

Gender and Ethnicity Balance: Regulatory and Ethical Expectations

While most BA/BE studies aim for a balanced population, many still include a majority of male subjects due to hormonal variability in women. Regulatory agencies increasingly encourage gender inclusion, but accept male-only designs when scientifically justified.

Ethnicity and genetic polymorphism can impact drug metabolism (e.g., CYP2D6, CYP3A4 variants). Therefore, when submitting data to global regulators, it’s ideal to ensure some ethnic diversity in the population. For global filings, sponsors often conduct studies in multiple regions or supplement data through bridging studies.

Sample Size Calculation: Linked to Population Variability

The selected study population directly affects the sample size. In healthy volunteers with low variability, a sample size of 18–36 is often sufficient. In contrast, for drugs with high intra-subject CV%, more subjects are needed—especially in parallel designs.

For example, assume a drug with 20% intrasubject variability. Using a two-period, two-sequence crossover design with 80% power and α = 0.05, around 24 evaluable subjects are needed. If dropout rates are expected at 10–15%, 28–30 subjects are enrolled.

Special Populations: When to Consider the Exception

In rare cases, BA/BE studies may be conducted in special populations. These include:

• Elderly patients: For drugs primarily prescribed to geriatrics
• Renal/hepatic impaired: When metabolism changes significantly
• Pediatric subjects: Usually waived unless essential for regulatory approval

These studies are always done with heightened ethics board oversight and require explicit informed consent/assent protocols. Food effect studies and single vs multiple-dose designs may influence whether such populations are involved in BA/BE assessments.

Ethics and Informed Consent for Subject Recruitment

Before initiating recruitment, the protocol must be approved by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB). The informed consent form (ICF) must clearly outline:

• The study’s purpose and design
• Possible risks (e.g., blood draws, drug reactions)
• Volunteer rights and compensation
• Withdrawal rights at any time without penalty

Subjects must be allowed sufficient time to consider participation. Illiterate volunteers require an impartial witness during the consent process. Ethics requirements are aligned with ICH E6(R2), the Declaration of Helsinki, and national clinical trial rules (e.g., CTRI guidelines in India).

Screening Procedures and Baseline Evaluation

Once inclusion criteria are met, subjects undergo detailed screening:

• Medical history and physical exam
• Vital signs: BP, HR, temperature
• 12-lead ECG
• Laboratory tests: CBC, LFT, RFT, serology (HIV, Hep B/C)
• Pregnancy tests for women

Baseline data also serves to eliminate outliers that may affect PK profiles. Screening data is documented and maintained in the Trial Master File (TMF) and subject source files. Screen failure logs should be kept as part of regulatory readiness.

Dropouts and Replacements: Managing the Study Population

Dropouts are inevitable in BA/BE studies, especially during washout or fasting periods. Protocols must clearly outline the strategy for dropouts, replacements, and evaluable vs safety populations. Subjects who vomit within 2 times the median T_max are often excluded from PK analysis per FDA guidance.

Examples:

• Subject #09 vomited at 0.75 hr; median T_max was 1.5 hr → exclude from PK
• Subject #14 missed a post-dose sample due to fainting → included in safety, not PK set

Conclusion: Strategic Selection of Study Population Ensures Validity

BA/BE studies may be relatively short and small in size, but their rigor begins with who you choose to include. Regulatory agencies evaluate the subject population closely, as variability, ethical compliance, and demographic justification all impact data acceptance.

Following a well-documented, regulatory-aligned subject selection process ensures credible bioequivalence results and faster approval timelines. Invest time in designing the right inclusion and exclusion criteria, and maintain thorough documentation throughout the trial process. Your study population is not just a group of volunteers—it is the backbone of your BE dossier.